OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based mostly in San Francisco that desires people to reside 10 years longer than what it calls a wholesome human lifespan.

Altman beforehand provided Retro Biosciences’ total seed spherical of $180 million. Now, the startup is elevating a $1 billion Sequence A that Altman is becoming a member of, the Financial Times studies.

Retro Biosciences, which says it plans to launch trials for medicine concentrating on illnesses like Alzheimer’s, not too long ago trained a model with OpenAI to show common cells into stem cells.

CEO Joe Betts-LaCroix informed the FT he needs to maneuver quick by discovering and growing a drug “within the 2020s.”

The startup joins different main billionaire-backed longevity efforts, together with Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by each Bezos and Peter Thiel.